T. Rowe Price Associates’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-307,837
| Closed | -$29.9M | – | 2575 |
|
|
2019
Q3 | $29.9M | Sell |
307,837
-386,859
| -56% | -$37.5M | ﹤0.01% | 1030 |
|
|
2019
Q2 | $71.1M | Buy |
694,696
+2,381
| +0.3% | +$244K | 0.01% | 759 |
|
|
2019
Q1 | $78.8M | Sell |
692,315
-1,278,451
| -65% | -$146M | 0.01% | 703 |
|
|
2018
Q4 | $77.1M | Sell |
1,970,766
-577,184
| -23% | -$22.6M | 0.01% | 675 |
|
|
2018
Q3 | $139M | Sell |
2,547,950
-485,182
| -16% | -$26.5M | 0.02% | 577 |
|
|
2018
Q2 | $251M | Sell |
3,033,132
-876,736
| -22% | -$72.6M | 0.04% | 411 |
|
|
2018
Q1 | $260M | Sell |
3,909,868
-217,093
| -5% | -$14.5M | 0.04% | 399 |
|
|
2017
Q4 | $212M | Buy |
4,126,961
+304,002
| +8% | +$15.6M | 0.03% | 448 |
|
|
2017
Q3 | $341M | Buy |
3,822,959
+650,561
| +21% | +$58M | 0.06% | 337 |
|
|
2017
Q2 | $190M | Sell |
3,172,398
-200,387
| -6% | -$12M | 0.03% | 452 |
|
|
2017
Q1 | $180M | Buy |
3,372,785
+331,069
| +11% | +$17.7M | 0.03% | 449 |
|
|
2016
Q4 | $152M | Buy |
3,041,716
+135,220
| +5% | +$6.75M | 0.03% | 480 |
|
|
2016
Q3 | $175M | Buy |
2,906,496
+248,309
| +9% | +$14.9M | 0.04% | 461 |
|
|
2016
Q2 | $136M | Buy |
2,658,187
+145,580
| +6% | +$7.44M | 0.03% | 488 |
|
|
2016
Q1 | $74.1M | Buy |
2,512,607
+459,679
| +22% | +$13.6M | 0.02% | 645 |
|
|
2015
Q4 | $93M | Buy |
2,052,928
+795,520
| +63% | +$36M | 0.02% | 577 |
|
|
2015
Q3 | $52.5M | Buy |
1,257,408
+126,112
| +11% | +$5.26M | 0.01% | 758 |
|
|
2015
Q2 | $65.9M | Sell |
1,131,296
-73,230
| -6% | -$4.27M | 0.01% | 744 |
|
|
2015
Q1 | $90.4M | Buy |
+1,204,526
| New | +$90.4M | 0.02% | 649 |
|